167 related articles for article (PubMed ID: 11181393)
1. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
Weig M; Müller FM
Antimicrob Agents Chemother; 2001 Mar; 45(3):966-8. PubMed ID: 11181393
[TBL] [Abstract][Full Text] [Related]
2. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of voriconazole against Candida species isolated in Taiwan.
Yang YL; Cheng HH; Lo HJ
Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
[TBL] [Abstract][Full Text] [Related]
4. Isolation, characterization and antifungal susceptibility pattern of Candida species causing oropharyngeal candidiasis in HIV positive patients.
Maninder J; Usha A
J Commun Dis; 2008 Sep; 40(3):177-81. PubMed ID: 19245155
[TBL] [Abstract][Full Text] [Related]
5. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis.
Vazquez JA; Peng G; Sobel JD; Steele-Moore L; Schuman P; Holloway W; Neaton JD
Clin Infect Dis; 2001 Oct; 33(7):1069-75. PubMed ID: 11528582
[TBL] [Abstract][Full Text] [Related]
6. Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients.
Nadagir SD; Chunchanur SK; Halesh LH; Yasmeen K; Chandrasekhar MR; Patil BS
Southeast Asian J Trop Med Public Health; 2008 May; 39(3):492-5. PubMed ID: 18564689
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods.
Cantón E; Pemán J; Gobernado M; Viudes A; Espinel-Ingroff A
Antimicrob Agents Chemother; 2005 Apr; 49(4):1593-6. PubMed ID: 15793148
[TBL] [Abstract][Full Text] [Related]
8. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
9. Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
Müller FM; Staudigel A; Salvenmoser S; Tredup A; Miltenberger R; Herrmann JV
Antimicrob Agents Chemother; 2007 Aug; 51(8):3014-6. PubMed ID: 17548494
[TBL] [Abstract][Full Text] [Related]
10. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
Sobel JD; Ohmit SE; Schuman P; Klein RS; Mayer K; Duerr A; Vazquez JA; Rampalo A;
J Infect Dis; 2001 Jan; 183(2):286-93. PubMed ID: 11204125
[TBL] [Abstract][Full Text] [Related]
11. Activity of fluconazole against Candida albicans isolates from HIV+ patients in a digestive candidosis turkey model.
Reynes J; Mallie M; Ravisse P; Bastide JM
J Med Vet Mycol; 1992; 30(5):363-7. PubMed ID: 1469537
[TBL] [Abstract][Full Text] [Related]
12. The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans.
Jin J; Guo N; Zhang J; Ding Y; Tang X; Liang J; Li L; Deng X; Yu L
Lett Appl Microbiol; 2010 Sep; 51(3):351-7. PubMed ID: 20681969
[TBL] [Abstract][Full Text] [Related]
13. [Azole resistance in Candida albicans].
Perea S
Rev Esp Quimioter; 2000 Sep; 13(3):314-7. PubMed ID: 11086283
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
[TBL] [Abstract][Full Text] [Related]
15. Emergence of Candida albicans fungemia during voriconazole therapy.
Mohammedi I; Thiebaut A; Piens MA; Argaud L; Martin O; Robert D
J Infect; 2005 Oct; 51(3):e83-4. PubMed ID: 16230209
[No Abstract] [Full Text] [Related]
16. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
[TBL] [Abstract][Full Text] [Related]
17. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
18. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole.
Quan H; Cao YY; Xu Z; Zhao JX; Gao PH; Qin XF; Jiang YY
Antimicrob Agents Chemother; 2006 Mar; 50(3):1096-9. PubMed ID: 16495278
[TBL] [Abstract][Full Text] [Related]
19. Influence of voriconazole and fluconazole on reconstituted multilayered oesophageal epithelium infected by Candida albicans.
Bernhardt J; Bernhardt H; Knoke M; Ludwig K
Mycoses; 2004 Aug; 47(7):330-7. PubMed ID: 15310340
[TBL] [Abstract][Full Text] [Related]
20. [Correlation between resistance testing and typing of Candida albicans--isolates from AIDS patients and chronic recurrent oral candidiasis].
Ruhnke M; Tennagen I; Engelmann E
Mycoses; 1994; 37 Suppl 1():60-3. PubMed ID: 7854368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]